ABSTRACT
Objective@#This study aimed to analyze the correlation between the immunoexpression of matrix metalloproteinase 9 (MMP-9) and tissue inhibitor of metalloproteinase-1 (TiMP1) in the uterosacral ligaments in patients with uterine prolapse. @*Methods@#This analytic-correlative cross-sectional study included 32 patients who were admitted at the Hasan Sadikin General Hospital from July to December 2013. Sixteen of the patients had uterine prolapse, while the rest did not. The patients underwent total hysterectomy, radical hysterectomy, or staging laparotomy. MMP-9 and TiMP1 expression in the uterosacral ligaments was measured via immunohistochemical staining. The median expression per field of view was calculated using a histoscore. @*Results@#MMP-9 expression in patients with uterine prolapse was found to be higher than that in the control group. Meanwhile, TiMP1 expression showed no significant difference between the groups. Spearman’s analysis showed a moderate correlation between the expression of MMP-9 and uterine prolapse incidence (P=0.02), with a correlation coefficient of 0.574. @*Conclusion@#There is a moderate correlation between MMP-9 expression and the incidence of uterine prolapse. It can be considered one of the primary etiologies of uterine prolapse.
ABSTRACT
Objective: To investigate the correlation between EFV and severity of coronary artery stenosis using cardiac-CT in CAD subjects at Hasan Sadikin Hospital Bandung. Methods: It is an analytical observational study with a crosssectional design using retrospective data with ANOVA and Chi-square statistical testing. The EFV and severity of coronary artery stenosis were quantified from diagnosed CAD subjects and underwent cardiac-CT in Hasan Sadikin Hospital Bandung from January2018-August 2018. Results: In 33 subjects there were 16 male (48.5%), 17 female (51.5%), there were 9 mild (27.3%), 9 moderate (27.3%), and 15 severe (45.5%) stenosis. Abnormal EFV (>125 ml) were 14 subjects (42.4%) found most in severe stenosis (30.3%). Chi-Square analysis showed that EFV had a significantly positive correlation with coronary artery stenosis (p=0.006), respectively. Conclusion: EFV demonstrated a positive correlation with the severity of coronary artery stenosis in CAD subjects using cardiac-CT at Hasan Sadikin Hospital, Bandung.
ABSTRACT
Aim: to observe the efficacy and safety of Polygeline colloid (Haemaccel) in adults with stage I - II of dengue haemorrhagic fever (DHF). Methods: an open, non-comparative clinical trial. The subjects were male or female between 17 - 55 years old, who fulfilled the criteria of stage I or II of DHF according to WHO and selected with consecutive sampling. Fluid treatments were given following this protocol: polygeline i.v. infusion: 500 ml over first 6 hours and continued with 500 ml for the next 18 hours, and maintained to 1000 mL/24 hours from day-2 until maximum day-5. Ringer's lactate infusion: 1000 mL/18 hours from the first day to maximum day-5, as maintenance. Efficacy and safety of polygeline colloid were evaluated using initial stabilization of haematocrite level, measured as percentage of clinical trial subject who has stabilization of haemodynamic status based on serial haematocrite levels examinations, total parenteral fluid required and length of hospitalization. Statisticial analysis was done using ANOVA test and post hoc analysis using Turkey test. Results: there were 43 subjects who completely participated in this study and included in analysis. From baseline levels, haematocrite decreased in first 6 hours during fluid treatment. This decrement persisted in 48 hours of observation. Statistical analysis with ANOVA test showed the significant differences of haematocrite level during observation (Sum of square between groups 495 and within group 4845, p= 0.000). Post hoc analysis with Turkey test showed significant differences of haematocrite level from baseline level to 48, 72 and 96 hours during observation periods. Conclusion: this pilot study showed that polygeline colloid was a safe initial fluid treatment and can be used for maintaining fluid adequacy in adults with stage I-II of DHF.